Purple Biotech PPBT 深 滬
交易中 09-24 11:47:25 美东时间
1.49
+0.005
+0.34%
華盛通- 最 高1.53
- 今 開1.46
- 成交量 6520股
- 最 低 1.46
- 昨 收 1.485
- 總市值 242.40万
- 52周最高 14.10
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 1.16
- 委 比 8.20%
- 總股本 162.69万
- 歷史最高 13900.00
- 量 比 0.29
- 振 幅 4.71%
- 歷史最低 1.46
- 每 手 1
- 風險率 2.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Purple Biotech Stock Gaining Wednesday?
Purple Biotech Ltd. (NASDAQ:PPBT) stock is surging on Wednesday following a favorable U.S. patent update. The U.S. Patent and Trademark Office granted the biotechnology company a Notice of Allowance regarding a crucial patent application that covers its tri-specific antibody constructs and their spe...
09-02 21:24
Why Is Purple Biotech (PPBT) Stock 42% Up Today?
Purple Biotech stock surged higher on Wednesday after the company announced a p...
09-02 21:22
Purple Biotech Issued Patent From U.S. Patent And Trademark Office For Its Application Covering Tri-Specific Antibody Constructs, Models
Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued ...
09-02 19:32
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17
HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target from $30 to $17.
08-08 02:10
Purple Biotech Q2 EPS $(0.35) Beats $(0.98) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.98) by 64.29 percent. This is a 91.25 percent increase over losses of $(4.00) per share from the same period last year.
08-07 19:07
Purple Biotech Presents New Cancer Immunotherapy Data at EACR 2026, Says IM1240 Data Support First Human Study in 2027
Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage oncology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of new preclinical data from its lea...
06-11 19:06
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Purple Biotech's IM1240, a CAPTN-3 platform candidate, showed superior pharmacokinetics and safety in non-human primate studies, with an 8-fold longer half-life and 16-fold greater exposure than the non-capped variant. It demonstrated anti-tumor activity in PD-1- and chemotherapy-resistant cancers, including head and neck, bladder, and lung cancers, with the NKG2A arm playing a key role. IM1240 induced immune structures linked to effective anti-t...
06-11 11:00
Purple Biotech Files $200M Mixed Securities Shelf
https://www.sec.gov/Archives/edgar/data/1614744/000121390026059665/ea0291624-f3_purple.htm
05-21 05:43
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 147.2% to ...
05-20 20:06
